Novel Four-Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor-Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic Outcome

摘要: Twenty human immunodeficiency virus-infected patients experiencing virologic failure of an indinavir- or ritonavir-containing treatment regimen were evaluated in a prospective, open-label study. Subjects received nelfinavir, saquinavir, abacavir, and either another nucleoside analog (n=10) nevirapine (n=10). Patients treated with the nevirapine-containing experienced significantly greater suppression at week 24 than those not (P=.04). Baseline phenotypic drug susceptibility was strongly correlated outcome both arms. baseline virus phenotypically sensitive to 2 3 drugs salvage load 0 1 (median week-24 change=-2.24 log -0.35 log, respectively; P=.01). In conclusion, non-nucleoside reverse transcriptase inhibitors may represent potent therapy regimens after indinavir ritonavir regimen. Phenotypic resistance testing provide useful tool for selecting more effective regimens.